FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000323755> ?p ?o ?g. }

• W2000323755 endingPage "649" @default.
• W2000323755 startingPage "642" @default.
• W2000323755 abstract "A phase I-II study to evaluate gene-mediated cytotoxic immunotherapy in newly diagnosed prostate cancer before radical prostatectomy was conducted in Monterrey, Mexico. First, to investigate delivery of adenovirus to the prostate, fluorescently labeled vector was injected into fresh prostatectomy specimens and distribution was visually analyzed. The optimal volume and site instillation was then used for transrectal ultrasound guided intraprostatic injection in 10 patients with adenocarcinoma scheduled for radical prostatectomy. Each received two apical and two basal 0.5 ml injections of AdV-tk for a total of 1 × 1011 vp followed by 14 days of prodrug. Nine patients continued to tumor resection: six high risk, one intermediate and two low risk. In vivo vector distribution was analyzed from the resected tissue of four patients. Patients were monitored for tumor progression and acute and long-term safety. For vector delivery, two apical and two basal injections of 0.5 ml led to optimal organ-wide distribution ex vivo and in vivo. Cytotoxicity was evidenced by transient rise in PSA and tumor histology. There were no significant adverse events deemed related to the treatment and no late toxicities after median follow-up of 11.3 years. All six high-risk patients had positive surgical margins and one had seminal vesicle involvement. Despite slow PSA rise post surgery in three of these patients, none developed metastases. The intermediate- and low-risk patients had complete resections and none have progressed. In conclusion, in vivo transrectal ultrasound guided instillation of an adenoviral vector into four sites in the prostate was practical as an outpatient procedure, well tolerated and led to distribution throughout the intraprostatic tumor mass. AdV-tk demonstrated no significant acute or late toxicities. Trends in PSA and disease progression conveyed the possibility of a sustained immune response against residual disease." @default.
• W2000323755 created "2016-06-24" @default.
• W2000323755 creator A5005264037 @default.
• W2000323755 creator A5018050764 @default.
• W2000323755 creator A5020368412 @default.
• W2000323755 creator A5024670184 @default.
• W2000323755 creator A5029652952 @default.
• W2000323755 creator A5038781912 @default.
• W2000323755 creator A5041589223 @default.
• W2000323755 creator A5041847366 @default.
• W2000323755 creator A5045169060 @default.
• W2000323755 creator A5049441274 @default.
• W2000323755 creator A5051302499 @default.
• W2000323755 creator A5070443349 @default.
• W2000323755 creator A5078627645 @default.
• W2000323755 creator A5080482111 @default.
• W2000323755 creator A5084479375 @default.
• W2000323755 date "2013-09-20" @default.
• W2000323755 modified "2023-10-18" @default.
• W2000323755 title "Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer" @default.
• W2000323755 cites W1964863866 @default.
• W2000323755 cites W1964948573 @default.
• W2000323755 cites W1972601062 @default.
• W2000323755 cites W1973758213 @default.
• W2000323755 cites W1994294989 @default.
• W2000323755 cites W2006258734 @default.
• W2000323755 cites W2012315955 @default.
• W2000323755 cites W2015582678 @default.
• W2000323755 cites W2022301248 @default.
• W2000323755 cites W2030622610 @default.
• W2000323755 cites W2040659915 @default.
• W2000323755 cites W2047612080 @default.
• W2000323755 cites W2054125735 @default.
• W2000323755 cites W2071879495 @default.
• W2000323755 cites W2090312211 @default.
• W2000323755 cites W2106415083 @default.
• W2000323755 cites W2106623789 @default.
• W2000323755 cites W2138304857 @default.
• W2000323755 cites W2142991244 @default.
• W2000323755 cites W2145829662 @default.
• W2000323755 cites W2151114651 @default.
• W2000323755 cites W2152529149 @default.
• W2000323755 cites W2158725014 @default.
• W2000323755 cites W2158734599 @default.
• W2000323755 cites W2169952373 @default.
• W2000323755 cites W2329581344 @default.
• W2000323755 cites W4252346155 @default.
• W2000323755 doi "https://doi.org/10.1038/cgt.2013.56" @default.
• W2000323755 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3842423" @default.
• W2000323755 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24052127" @default.
• W2000323755 hasPublicationYear "2013" @default.
• W2000323755 type Work @default.
• W2000323755 sameAs 2000323755 @default.
• W2000323755 citedByCount "31" @default.
• W2000323755 countsByYear W20003237552015 @default.
• W2000323755 countsByYear W20003237552016 @default.
• W2000323755 countsByYear W20003237552017 @default.
• W2000323755 countsByYear W20003237552018 @default.
• W2000323755 countsByYear W20003237552019 @default.
• W2000323755 countsByYear W20003237552020 @default.
• W2000323755 countsByYear W20003237552021 @default.
• W2000323755 countsByYear W20003237552022 @default.
• W2000323755 countsByYear W20003237552023 @default.
• W2000323755 crossrefType "journal-article" @default.
• W2000323755 hasAuthorship W2000323755A5005264037 @default.
• W2000323755 hasAuthorship W2000323755A5018050764 @default.
• W2000323755 hasAuthorship W2000323755A5020368412 @default.
• W2000323755 hasAuthorship W2000323755A5024670184 @default.
• W2000323755 hasAuthorship W2000323755A5029652952 @default.
• W2000323755 hasAuthorship W2000323755A5038781912 @default.
• W2000323755 hasAuthorship W2000323755A5041589223 @default.
• W2000323755 hasAuthorship W2000323755A5041847366 @default.
• W2000323755 hasAuthorship W2000323755A5045169060 @default.
• W2000323755 hasAuthorship W2000323755A5049441274 @default.
• W2000323755 hasAuthorship W2000323755A5051302499 @default.
• W2000323755 hasAuthorship W2000323755A5070443349 @default.
• W2000323755 hasAuthorship W2000323755A5078627645 @default.
• W2000323755 hasAuthorship W2000323755A5080482111 @default.
• W2000323755 hasAuthorship W2000323755A5084479375 @default.
• W2000323755 hasBestOaLocation W20003237551 @default.
• W2000323755 hasConcept C121608353 @default.
• W2000323755 hasConcept C126322002 @default.
• W2000323755 hasConcept C126894567 @default.
• W2000323755 hasConcept C141071460 @default.
• W2000323755 hasConcept C150903083 @default.
• W2000323755 hasConcept C207001950 @default.
• W2000323755 hasConcept C26291073 @default.
• W2000323755 hasConcept C2776235491 @default.
• W2000323755 hasConcept C2777701055 @default.
• W2000323755 hasConcept C2779466945 @default.
• W2000323755 hasConcept C2780192828 @default.
• W2000323755 hasConcept C2781182431 @default.
• W2000323755 hasConcept C71924100 @default.
• W2000323755 hasConcept C86803240 @default.
• W2000323755 hasConceptScore W2000323755C121608353 @default.
• W2000323755 hasConceptScore W2000323755C126322002 @default.
• W2000323755 hasConceptScore W2000323755C126894567 @default.
• W2000323755 hasConceptScore W2000323755C141071460 @default.

• next